Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT007 versus emicizumab prophylaxis in hemophilia A
2025-522435-33-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial in hemophilia A comparing NXT007 prophylaxis with Emicizumab prophylaxis (2 arms). Primary endpoint: Annualized number of treated bleeds. Planned start Jun 2026; status: authorised.
02
Drugs
zemocimigemicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2025-522435-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522435-33-00.